DUSA Pharmaceuticals to Present at The Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York.WILMINGTON, Mass. -- DUSA DUSA Deputy Under Secretary of the Army DUSA Deakin University Student Association DUSA Dundee University Students' Association (Scotland) DUSA Designated Unclassified Subject Area Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on NMS See NetWare Management System. :DUSA) announced today that Dr. Geoff Shulman, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Mr. Bob Doman, President & COO, will be presenting at the Rodman & Renshaw Techvest Global Healthcare Conference on Monday, November 7th at 3:30 p.m. at The New York Palace
Interested investors can access the live audio webcast of the presentation at www.dusapharma.com. A replay of the presentation will be available and will be archived for 90 days thereafter. DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in the development of Levulan(R) Photodynamic Therapy (PDT PDT abbr. Pacific Daylight Time PDT Pacific Daylight Time PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del Pacífico PDT ) and Photodetection (PD) for multiple medical indications, with its primary focus in dermatology. PDT and PD utilize light-activated compounds such as Levulan(R) to induce a therapeutic or detection effect. DUSA is a world leader in topically or locally applied PDT and PD. The Company maintains offices in Wilmington, MA, Valhalla, NY, and Toronto, Ontario. Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements relate to a planned presentation by Dr. Geoff Shulman and Mr. Robert Doman and the availability of the presentation on the web. Such risks and uncertainties include, but are not limited to, commencement of the conference, ability of Dr. Shulman and Mr. Doman to be present at the conference, and other risks identified in DUSA's SEC filings from time to time. DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion